id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-E-1091-0008,FDA,FDA-2021-E-1091,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-13T05:00:00Z,2025,1,2025-01-13T05:00:00Z,,2025-01-13T20:15:50Z,,0,0,09000064868b81fb
FDA-2021-E-1091-0007,FDA,FDA-2021-E-1091,Letter from U. S. Patent and Trademark Office,Other,Letter(s),2024-03-06T05:00:00Z,2024,3,2024-03-06T05:00:00Z,,2024-03-06T18:42:43Z,,0,0,09000064863ef547
FDA-2021-E-1091-0006,FDA,FDA-2021-E-1091,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-01-18T05:00:00Z,2024,1,2024-01-18T05:00:00Z,,2024-01-18T21:29:54Z,,0,0,09000064863a94ba
FDA-2021-E-1091-0005,FDA,FDA-2021-E-1091,Determination of Regulatory Review Period for Purposes of Patent Extension; Pemazyre,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T14:47:16Z,2023-26996,0,0,0900006486316628
FDA-2021-E-1091-0004,FDA,FDA-2021-E-1091,Letter to U S Patent and Trademark Office,Other,Letter(s),2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,,2022-09-08T16:38:08Z,,0,0,09000064852ce9e0
FDA-2021-E-1091-0002,FDA,FDA-2021-E-1091,Patent Extension Application from Fish & Richardson P.C. (on behalf of Incyte Corporation),Other,Application,2021-10-12T04:00:00Z,2021,10,2021-10-12T04:00:00Z,,2021-10-12T14:56:45Z,,0,0,0900006484dc20b5
FDA-2021-E-1091-0001,FDA,FDA-2021-E-1091,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-10-12T04:00:00Z,2021,10,2021-10-12T04:00:00Z,,2021-10-12T14:56:37Z,,0,0,0900006484dc24f8
FDA-2021-E-1091-0003,FDA,FDA-2021-E-1091,Appendix A re Patent Extension Application from Fish & Richardson P.C. (on behalf of Incyte Corporation),Supporting & Related Material,Background Material,2021-10-12T04:00:00Z,2021,10,,,2021-10-12T14:56:53Z,,0,0,0900006484dc20b7